Posted by: Georgia Retina in News

SUSVIMO delivers continuous treatment for wet AMD, reducing the need for frequent injections

ATLANTA – (Oct. 2024) Georgia Retina today announced Dr. Gregory Lee as among the first doctors in Georgia to utilize the SUSVIMO implant, the first and only device for people with wet age-related macular degeneration (wet AMD) that continuously delivers treatment.

SUSVIMO is an innovative, minimally invasive treatment for wet AMD, a chronic eye condition that can lead to blurred vision, a central blind spot and vision loss. The implant releases medication to the eye at a steady rate over the course of six months. With just two efficient treatments per year, the SUSVIMO implant reduces the need for frequent injections, slowing the progression of wet AMD and allowing patients to achieve a better quality of life.

“SUSVIMO is a fantastic option for patients who are burdened by the frequency of treatment for their macular degeneration,” said Dr. Gregory Lee, Georgia Retina ophthalmologist. “It’s a new platform for sustained, steady delivery of the medicine patients need so they have less injections and office visits. It allows them to have flexibility for their lives and removes the danger of a missed appointment or injection for those patients who need frequent treatment.”

SUSVIMO is placed in the eye during a one-time surgical procedure and is not visible to others, as the eyelid lies naturally over it. Throughout the six-month cycle, SUSVIMO releases ranibizumab, a trusted medicine by retina specialists that has been used for years and proven to effectively treat wet AMD. With SUSVIMO, patients are provided with the same vision results as monthly injections.

“I’m just thankful that there was an opportunity to take part in this cutting-edge advancement in technology for macular degeneration,” said Vicki R., Georgia Retina SUSVIMO patient. “I’m amazed at how good the recovery is going.”

Georgia Retina remains committed to serving patients throughout Greater Atlanta and Georgia by implementing the latest advancements in technologies and procedures like SUSVIMO. If interested, patients are encouraged to speak with a retina specialist to determine if they are eligible for the treatment.